Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dutch Competition Body Urged To Fine Leadiant Over 'Exorbitant' Orphan Drug Price

Executive Summary

The Dutch Pharmaceutical Accountability Foundation has asked the country's competition authority to take action against Leadiant Biosciences over the company's pricing of an orphan drug for a rare genetic disease. 
Advertisement

Related Content

Dutch Move On Pharmacy Compounding Could Deter Orphan Drug Launches
Dutch Insurer Seeks €4m from AZ Over ‘High’ Seroquel Price
New Dutch ‘Excessive Price’ Watchdog Targets Leadiant’s Orphan Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS123818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel